Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.

ABSTRACT:

Background

As the influenza A H1N1 pandemic emerged in 2009, children were found to experience high morbidity and mortality and were prioritized for vaccination. This multicenter, randomized, double-blind, age-stratified trial assessed the safety and immunogenicity of inactivated influenza A(H1N1)pdm09 vaccine in healthy children aged 6 months to 17 years.

Methods

Children received 2 doses of approximately 15 or 30 µg hemagglutin antigen 21 days apart. Reactogenicity was assessed for 8 days after each dose, adverse events through day 42, and serious adverse events or new-onset chronic illnesses through day 201. Serum hemagglutination inhibition titers were measured on days 0 (prevaccination), 8, 21, 29 and 42.

Results

A total of 583 children received the first dose an

SUBMITTER: Kotloff KL 

PROVIDER: S-EPMC4166548 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature